newsfilter
← Earnings
Earnings Releases·

First Tracks Biotherapeutics — Third Quarter 2026 Earnings Summary

  • Q3 2026 net loss narrowed to $31.4 million ($0.88/share) from $41.9 million ($1.50/share) in Q3 2025, driven by a 28% reduction in R&D expenses to $23.8 million, though G&A expenses rose to $9.0 million due to separation-related legal costs.
  • Cash and investments declined to $155.6 million as of September 30, 2026, from $311.6 million at year-end 2025, but a $200 million private placement completed in October 2026 raised pro forma cash to $343 million.
  • ANB033 Phase 1b Cohort 1 data in celiac disease showed statistically significant improvements in mucosal healing and symptom reduction with no safety signals, prompting plans to initiate late-stage trials in 2027 and report Cohort 2 top-line data in Q1 2027.
  • Strategic outlook includes initiating ANB033 Phase 2 development in vitiligo and an additional indication in H1 2027, while Rosnilimab is being evaluated for return-on-equity-maximizing options and ANB101 Phase 1a is complete pending further development decisions.
Company
FIRST TRACKS BIOTHERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology